Abstract: The present disclosure describes a method for treating or preventing an inflammatory ocular surface disease or disorder, such as ocular graft-versus-host disease, dry eye, meibomian gland disease, thyroid eye disease, blepharitis, Sjogren's syndrome, peripheral ulcerative keratitis, or Stevens-Johnson syndrome, in a human subject in need thereof, the method comprising (a) administering a topical progesterone composition to the forehead of the subject; (b) administering punctal plugs to the subject; and (c) administering a opical corticosteroid composition, such as loteprednol etabonate ointment, to the eye of the subject. Such administration methods may also be useful in improving corneal health before cataract surgery and/or promoting healing of the cornea after cataract surgery.

Abstract: The present disclosure describes a method for treating a disease or condition selected from Parkinson's disease, traumatic brain injury, concussion, chronic traumatic encephalopathy, spinal cord injury, Sjögren's syndrome, Hashimoto's disease, lupus, psoriasis, psoriatic arthritis, rheumatoid arthritis, graft vs. host disease, hypogonadism, male metabolic syndrome, menopausal hormone insufficiency, and ocular surface disease, the method comprising topical administration of a testosterone composition to the forehead.

Abstract: A method for rapid delivery of an active compound to innervate a cranial nerve of a subject. Also provided is a method for treating a disease or condition by topically applying a pharmaceutical composition to the face excluding the palpebral part of the eye, in an amount effective for treating the disease or condition.

Abstract: A method for treating a symptom of a neurodegenerative condition. The method includes topically administering a composition that contains a sex steroid or a cannabinoid or a mixture of both to the forehead, to an area of the outer ear of the subject not including the ear canal, or to both of these anatomical locations. The symptom treatable by the method is a motor symptom or a non-motor symptom.

Abstract: The invention relates to compositions and methods for treating eye diseases and disorders. More specifically, the invention provides compositions comprising progesterone and methods of treating ocular surface diseases and disorders comprising applying such compositions topically.

Abstract: A method for treating a symptom of a neurodegenerative condition. The method includes topically administering a composition that contains a sex steroid or a cannabinoid or a mixture of both to the forehead, to an area of the outer ear of the subject not including the ear canal, or to both of these anatomical locations. The symptom treatable by the method is a motor symptom or a non-motor symptom.

Abstract: A method for treating radiotherapy- or chemotherapy-induced cognitive or emotional impairment by topically administering a cannabinoid. Also provided is a method for treating a tumor by topically administering a cannabinoid together with radiotherapy and/or chemotherapy.

Abstract: A method for rapid delivery of an active compound to innervate a cranial nerve of a subject. Also provided is a method for treating a disease or condition by topically applying a pharmaceutical composition to the face excluding the palpebral part of the eye, in an amount effective for treating the disease or condition.

Abstract: The invention relates to compositions and methods for treating eye diseases and disorders. More specifically, the invention provides compositions comprising progesterone and methods of treating ocular surface diseases and disorders comprising applying such compositions topically.

Abstract: A method for rapid delivery of an active compound to innervate a cranial nerve of a subject. Also provided is a method for treating a disease or condition by topically applying a pharmaceutical composition to the face excluding the palpebral part of the eye, in an amount effective for treating the disease or condition.

Abstract: A method for treating radiotherapy- or chemotherapy-induced cognitive or emotional impairment by topically administering a cannabinoid. Also provided is a method for treating a tumor by topically administering a cannabinoid together with radiotherapy and/or chemotherapy.

Abstract: A kit or plurality of dosing regimens formulated for treating opioid dependence while minimizing withdrawal symptoms includes a plurality of dosage forms of an opioid or a pharmaceutically acceptable salt thereof containing an initial dosing series of the opioid sufficient to minimize withdrawal symptoms and a dosing amount of the opioid in each subsequent decreasing dosing series provides doses to be taken at least two times per day and for at least two days that when administered ensures that the lowest concentration level in the blood of the opioid for the subsequent dosing series is equal to at least ninety-five percent of the lowest concentration level in the blood of the immediately preceding dosing series and wherein the quantity of dosage forms is sufficient for administration for no less than sixty days.

Abstract: A method for rapid delivery of an active compound to innervate a cranial nerve of a subject. Also provided is a method for treating a disease or condition by topically applying a pharmaceutical composition to the face excluding the palpebral part of the eye, in an amount effective for treating the disease or condition.

Abstract: A method of reducing the concentration of a chemical or drug substance in the blood plasma comprising titrating an initial peak concentration of the chemical or drug substance in the blood for a predefined dosing period, titrating a lowest concentration level of the chemical or drug substance in the blood immediately before the end of the dosing period, and providing a plurality of subsequent dosing periods where each subsequent dosing period requires administration of a dosing amount of the chemical or drug substance and titrating of the peak concentration and the lowest concentration level to ensure that the lowest concentration level of the chemical or drug substance in the blood plasma for the subsequent dosing period is decreased by not more than five percent of the lowest concentration level of the previous dosing period and where the plurality of dosing periods added together is seventy days or more.

Abstract: The invention relates to compositions and methods for treating eye diseases and disorders. More specifically, the invention provides compositions comprising progesterone and methods of treating ocular surface diseases and disorders comprising applying such compositions topically.

Abstract: A method for preventing, treating, or ameliorating pruritus caused by skin, mucosa, or systemic disorder. The method comprises administering to a subject with pruritus or topically applying to an affected area with pruritus an effective amount of a formulation consisting essentially of a phenylbutyric acid or short-chain fatty acid derivative and a pharmaceutically acceptable carrier, salt or solvate thereof.

Abstract: Disclosed are a composition and a method for treating skin disorders, including rosacea, pityriasis rosea, erythema, rhinophyma, and rosacea-associated disorders including pimples, papules, pustules, and telangiectasia.

Abstract: A method of reducing the concentration of a chemical or drug substance in the blood plasma comprising titrating an initial peak concentration of the chemical or drug substance in the blood for a predefined dosing period, titrating a lowest concentration level of the chemical or drug substance in the blood immediately before the end of the dosing period, and providing a plurality of subsequent dosing periods where each subsequent dosing period requires administration of a dosing amount of the chemical or drug substance and titrating of the peak concentration and the lowest concentration level to ensure that the lowest concentration level of the chemical or drug substance in the blood plasma for the subsequent dosing period is decreased by not more than five percent of the lowest concentration level of the previous dosing period and where the plurality of dosing periods added together is seventy days or more.

Abstract: Disclosed are compositions and methods for skincare, e.g., reducing skin wrinkles and for treating skin disorders.

Abstract: A method of reducing the concentration of a chemical or drug substance in the blood plasma that targets the same or similar receptors as the normal neurotransmitters in the central or peripheral nervous system includes titrating an initial peak concentration of the chemical or drug substance in the blood for a predefined dosing period, titrating a lowest concentration level of the chemical or drug substance in the blood immediately before the end of the dosing period, and providing a plurality of subsequent dosing periods where each subsequent dosing period requires administration of a dosing amount of the chemical or drug substance and titrating of the peak concentration and the lowest concentration level to ensure that the lowest concentration level of the chemical or drug substance in the blood plasma for the subsequent dosing period is decreased by not more than five percent of the lowest concentration level of the previous dosing period and where the plurality of dosing periods added together extends the